Top Markets
#1 Status Status +19.55%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.58%
#3 GoPlus Security GoPlus Security +17.93%
#4 Wrapped NXM Wrapped NXM +14.89%
#5 Bedrock Bedrock +12.87%
#6 BankrCoin BankrCoin +12.81%
#7 Ontology Gas Ontology Gas +11.52%
#8 Pons Pons +9.76%
#9 DMT-NAT DMT-NAT +8.45%
#10 Janction Janction +7.35%
Coin of the day
Status Status
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Polydex Pharmaceuticals Limited Polydex Pharmaceuticals Limited

Polydex Pharmaceuticals Limited

POLXF
Rangering i aksjer #33818
Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was... Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was incorporated in 1979 and initially operated as Polydex Chemicals Limited before adopting its current name in March 1984. PPL specializes in the research, development, manufacturing, and global marketing of biotechnology-derived products for the human pharmaceutical sector. Beyond its human health focus, PPL also produces vital pharmaceutical intermediates for the veterinary industry. Its core product line centers on dextran and its various derivatives. Notable examples include iron dextran, a compound administered to newborn pigs to combat anemia, and dextran sulphate, a specialized chemical derivative crucial for biotechnology applications and the broader pharmaceutical sector. Furthermore, the company is actively developing Ushercell, a high molecular weight cellulose sulphate. This innovative product is designed for topical vaginal use, primarily aimed at preventing the transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. PPL's portfolio further extends to supplying ferric hydroxide and hydrogenated dextran solutions. Products reach the market through a combination of independent distributors, wholesalers, and direct sales channels to various companies.
Aksjekurs
$1.99
Sist synkronisert: 2023-08-07
Markedsverdi
$6.82M
Endring (1 dag)
0.30%
Endring (1 år)
0.00%
Land
CA
Handel Polydex Pharmaceuticals Limited (POLXF)

Kategori

Healthcare
P/E-forhold for Polydex Pharmaceuticals Limited (POLXF)
P/E-forhold per 2026 TTM: 0
Ifølge Polydex Pharmaceuticals Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Polydex Pharmaceuticals Limited fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.